Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PDGFR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
| Gene Symbol | PDGFR |
| Function | PDGFR-beta (PDGFRB) is a receptor tyrosine kinase that translates platelet-derived growth-factor ligands into pericyte survival, vascular maturation, and neurovascular homeostasis programs. |
| Pathways | MAPK signaling, PI3K-AKT-mTOR signaling, glymphatic clearance, blood-brain barrier |
| UniProt ID | P09619 |
| GeneCards | PDGFR |
| Human Protein Atlas | PDGFR |
| Associated Diseases | Huntington's disease, glioblastoma |
| Interactions | PI3K, ERK, MAPK, GBM, IL2 |
| KG Connections | 32 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
PDGFR(["PDGFR"])
style PDGFR fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff
Glioblastoma["Glioblastoma"]
PI3K(["PI3K"])
glioblastoma["glioblastoma"]
pericytes(["pericytes"])
MAPK_signaling(("MAPK signaling"))
PI3K_AKT_mTOR_signaling(("PI3K-AKT-mTOR signaling"))
Alzheimer_s_disease["Alzheimer's disease"]
neurodegeneration["neurodegeneration"]
glymphatic_clearance(("glymphatic clearance"))
Huntington_s_disease(["Huntington's disease"])
blood_brain_barrier["/"blood-brain barrier"/"]
ERK(["ERK"])
MAPK["MAPK"]
PDGFR -->|"associated_with"| Glioblastoma
PDGFR -->|"activates"| PI3K
PDGFR -->|"associated_with"| glioblastoma
PDGFR -->|"expressed_in"| pericytes
PDGFR -->|"participates_in"| MAPK_signaling
PDGFR -->|"participates_in"| PI3K_AKT_mTOR_signaling
PDGFR -->|"regulates"| PI3K
PDGFR -->|"regulates"| Alzheimer_s_disease
PDGFR -->|"protects_against"| neurodegeneration
PDGFR -->|"participates_in"| glymphatic_clearance
PDGFR -->|"associated_with"| Huntington_s_disease
PDGFR -->|"participates_in"| blood_brain_barrier
ERK -->|"activates"| PDGFR
MAPK -->|"activates"| PDGFR
classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
classDef drug fill:#1a2a2a,stroke:#80cbc4,color:#e0e0e0
class Glioblastoma disease
class PI3K protein
class glioblastoma disease
class pericytes protein
class MAPK_signaling pathway
class PI3K_AKT_mTOR_signaling pathway
class Alzheimer_s_disease disease
class neurodegeneration disease
class glymphatic_clearance pathway
class Huntington_s_disease protein
class blood_brain_barrier mechanism
class ERK protein
class MAPK gene| Target | Relation | Type | Str |
|---|---|---|---|
| PI3K | activates | protein | 0.70 |
| glioblastoma | associated_with | disease | 0.70 |
| PI3K | causes | gene | 0.60 |
| glioblastoma | causes | disease | 0.60 |
| PI3K | inhibits | gene | 0.60 |
| glioblastoma | inhibits | disease | 0.60 |
| T cells | expressed_in | cell_type | 0.60 |
| oxidative stress response | participates_in | pathway | 0.60 |
| ubiquitin-proteasome | participates_in | pathway | 0.60 |
| oligodendrocytes | expressed_in | cell_type | 0.60 |
| stem cells | expressed_in | cell_type | 0.60 |
| Alzheimer's disease | biomarker_for | disease | 0.60 |
| neuroinflammation | biomarker_for | disease | 0.60 |
| endothelial cells | expressed_in | cell_type | 0.60 |
| multiple sclerosis | biomarker_for | disease | 0.60 |
| pericytes | expressed_in | cell_type | 0.55 |
| MAPK signaling | participates_in | pathway | 0.55 |
| PI3K-AKT-mTOR signaling | participates_in | pathway | 0.55 |
| PI3K | regulates | gene | 0.55 |
| Alzheimer's disease | regulates | disease | 0.55 |
| neurodegeneration | protects_against | disease | 0.55 |
| glymphatic clearance | participates_in | pathway | 0.55 |
| Huntington's disease | associated_with | disease | 0.55 |
| blood-brain barrier | participates_in | pathway | 0.55 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Pericyte Contractility Reset via Selective PDGFR-β Agonism | 0.443 | neurodegeneration | Perivascular spaces and glymphatic clear |
Scientific analyses that reference this entity
No analyses mention this entity
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic [PMID:40848726] | Zhao S, Li R, Xia Y, Wang X, Liu Z, Chu | Cell Stem Cell | 2025 | 1 |
| Neurovascular unit, neuroinflammation and neurodegeneration markers in brain dis [PMID:39526043] | Kempuraj D, Dourvetakis KD, Cohen J, Val | Front Cell Neurosci | 2024 | 1 |
| The Genetics of Primary Familial Brain Calcification: A Literature Review. [PMID:37446066] | Chen SY, Ho CJ, Lu YT, Lin CH, Lan MY, T | Int J Mol Sci | 2023 | 1 |
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| Decoding myofibroblast origins in human kidney fibrosis. [PMID:33176333] | Kuppe C, Ibrahim MM, Kranz J, Zhang X, Z | Nature | 2021 | 1 |
| APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. [PMID:32376954] | Montagne A, Nation DA, Sagare AP, Barisa | Nature | 2020 | 1 |
| Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990] | Keller A | Annual review of physiology | 2026 | 0 |
| A FZD4/LRP5 agonist restores pericyte coverage and vascular integrity by increas [PMID:41890033] | Levey J, Howe M, Douglas K, Odame E, Raj | bioRxiv : the preprint server | 2026 | 0 |
| Immunological mechanisms and therapeutic approaches in pulmonary fibrosis. [PMID:41951242] | Nell LM, Hendriks RW, Wijsenbeek MS, Cor | Eur Respir Rev | 2026 | 0 |
| Nano-Enabled Fluorescence Switching: A Novel Strategy for PDGFRβ Detection and T [PMID:41884335] | Fu X, Fan J, Chen H, Zheng Y, Liu Y, Zha | Research (Washington, D.C.) | 2026 | 0 |
| Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129] | Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu | Clinical & experimental ophtha | 2026 | 0 |
| Central nervous system pericytes express soluble ST2 in inflammation and injury. [PMID:41857656] | Jansson D, Highet B, Li S, Stevenson TJ, | Molecular brain | 2026 | 0 |
| Astrocyte-Glioblastoma Stem Cell Interactions via Extracellular Vesicles Contrib [PMID:41712235] | Shirai Y, Tsuda M, Wang L, Oda Y, Sugizn | Pathology international | 2026 | 0 |
| The role of endothelial cell-pericyte interactions in vascularization and diseas [PMID:38246244] | Li G, Gao J, Ding P, Gao Y | Journal of advanced research | 2025 | 0 |
| Pericytes in Brain Homeostasis: Developmental Roles and Adult Functions. [PMID:41351407] | Drozd U, Vechkapova S, Lanshakov D | Frontiers in bioscience (Landm | 2025 | 0 |
| Pericyte-derived fibrotic scarring is conserved across diverse central nervous s [PMID:34535655] | Dias DO, Kalkitsas J, Kelahmetoglu Y, Es | Nature communications | 2021 | 0 |
| Blood-brain barrier breakdown is an early biomarker of human cognitive dysfuncti [PMID:30643288] | Nation DA, Sweeney MD, Montagne A, Sagar | Nature medicine | 2019 | 0 |
| Pericytes in Primary Familial Brain Calcification. [PMID:31147881] | Zarb Y, Franzoso FD, Keller A | Advances in experimental medic | 2019 | 0 |
| Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury. [PMID:29502968] | Dias DO, Kim H, Holl D, Werne Solnestam | Cell | 2018 | 0 |
| Clarifying off-target effects for torcetrapib using network pharmacology and rev [PMID:23228038] | ["Fan S", "Geng Q", "Pan Z", "Li X", "Ti | BMC systems biology | 2012 | 0 |